Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

Get CLEATUSFree Trial

Get CLEATUSFree Trial

Search

Top

Back to Contracts

Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

Active

Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Health And Human Services → National Institutes Of HealthView Agency

NAICS

N/A

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedJul 28

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → National Institutes Of Health

Contacts1 person available

OfficeUS

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health

View Agency Profile

Office AddressUS

Contacts

ITCR Mailbox

contact@example.gov

+1 (555) 000-0000

Full Description

Show more

NCI intends to release a Notice of Funding Opportunity (NOFO) that serves to continue the advancement and sustainment of informatics tools, software, and research resources that enable the acquisition, management, analysis, visualization, and interpretation of data across the cancer research continuum, including cancer biology, diagnosis and treatment, early detection, risk assessment and prevention, cancer control, and epidemiology. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this intended NOFO supports technologies that have progressed beyond initial prototyping and pilot development, demonstrate the potential for broad and significant impact in cancer research, and provide compelling reasons for further enhancement, optimization, dissemination, or sustainment.

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

INCLUDE Project: Omics Phenotypes Related to Down Syndrome (X01 Clinical Trial Not Allowed)

POSTED

DEADLINE

Limited Competition: Institutional Mentored Research Career Development Program for the Clinical and Translational Science Awards ProgramThe National Institutes of Health is forecasting a limited competition for the Institutional Mentored Research Career Development Program under the Clinical and Translational Science Awards Program, aimed at advancing the careers of later-stage postdoctoral fellows and junior faculty dedicated to independent research in clinical and translational science. The program seeks to establish institutional frameworks that provide structured mentoring, training, and research support to ensure timely progression and long-term engagement in transformative health research that bridges laboratory discoveries with real-world patient and public health outcomes. Funding is authorized under Sections 301 and 405 of the Public Health Service Act and governed by federal regulations including 42 CFR Part 52 and 2 CFR Part 200. Only eligible organizations may apply, and submissions will undergo standard NIH peer review, with awards granted exclusively to meritorious proposals. This funding opportunity is part of the broader Congressionally mandated CTSA initiative designed to build a nationwide network of academic medical centers equipped to accelerate the translation of scientific innovation into clinical and community health improvements. The forecast was posted on July 20, 2026, and inquiries should be directed to the Division of Clinical Innovation at NCATS via the designated email address. All applications must comply with NIH guidelines and are subject to the terms of a limited competition, with no public solicitation beyond the eligible pool of institutions.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant for the Clinical and Translational Science Awards ProgramThe National Institutes of Health, under the Department of Health and Human Services, is forecasting a limited competition for the Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant aimed at advancing clinical and translational science. This initiative supports accredited academic medical centers in developing comprehensive training programs for predoctoral and postdoctoral researchers, equipping them with the skills and infrastructure necessary to translate scientific discoveries into effective patient care and public health interventions. The program is aligned with the broader Congressionally mandated Clinical and Translational Science Award (CTSA) initiative, which fosters a national network of institutions dedicated to accelerating the movement of research from laboratory to clinic and community. Funding is authorized under Sections 301 and 405 of the Public Health Service Act and governed by federal regulations including 42 CFR Part 52 and 2 CFR Part 200. Only eligible organizations invited through the limited competition may submit applications, which will undergo standard NIH peer review to determine merit and funding eligibility. The opportunity is managed by the Division of Clinical Innovation at the National Center for Advancing Translational Sciences, with inquiries directed to a designated point of contact. The forecast was posted on July 20, 2026, and interested parties are encouraged to review eligibility criteria and application guidelines through the official Grants.gov portal.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Limited Competition: Research Education Program for the Clinical and Translational Science Awards ProgramThe Congressionally mandated Clinical and Translational Science Award Program aims to accelerate the translation of scientific discoveries into practical treatments, diagnostics, and health interventions that enhance patient and public health by establishing a national network of academic medical centers equipped with the infrastructure, expertise, training, and collaborative frameworks necessary to bridge laboratory research with clinical and community practice. This forecasted limited competition seeks to support research education activities that complement and strengthen the training of a skilled workforce capable of addressing the nation’s demands in biomedical, behavioral, and clinical research, aligning with the broader goals of the CTSA Program. Awards will be issued under the authority of Sections 301 and 405 of the Public Health Service Act as amended and governed by Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. Only eligible organizations may apply, and submissions will undergo the National Institutes of Health’s standard peer-review process, with funding reserved for the most meritorious proposals. The opportunity is open to a restricted pool of applicants as defined in the eligibility criteria, with applications to be submitted through the official grants portal, and inquiries should be directed to the Division of Clinical Innovation at NCATS.

Administration of Public Health Programs

POSTED

DEADLINE

Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational ScienceThe Congressionally mandated Clinical and Translational Science Award Program aims to accelerate the translation of scientific discoveries into practical health solutions by funding a national network of academic medical centers that provide the infrastructure, expertise, training, and collaborative environment necessary to move research from the laboratory into clinical practice and community health. Within this program, the High Impact Specialized Innovation Programs are designed to support unique, high-value capabilities, research platforms, or resources that address critical gaps or persistent roadblocks in clinical and translational science at designated CTSA hubs. These initiatives are intended to deliver timely, transformative advances that enhance the overall efficiency and impact of the CTSA network. Awards under this forecast are authorized under Sections 301 and 405 of the Public Health Service Act and governed by federal regulations including 42 CFR Part 52 and 2 CFR Part 200. This is a limited competition forecast, meaning only pre-eligible organizations may apply, and applications will undergo NIH’s standard peer-review process. Only those deemed meritorious will be considered for funding. The National Institutes of Health, through the Department of Health and Human Services and the Division of Clinical Innovation at NCATS, is soliciting applications with a forecast date of July 20, 2026, and inquiries should be directed to the provided point of contact.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Clinical and Translational Science AwardThe Congressionally mandated Clinical and Translational Science Award (CTSA) Program aims to strengthen the national infrastructure for accelerating the translation of scientific discoveries into practical treatments, diagnostics, and health interventions that enhance patient and public health. This initiative funds a network of academic medical centers to provide the essential resources, expertise, training, and collaborative frameworks needed to bridge the gap between laboratory research and clinical practice, as well as community health implementation. The reissuance of the Notice of Funding Opportunity is designed to support a comprehensive CTSA Hub that fosters an integrated environment for research and training in clinical and translational science, while promoting the development, testing, and broad adoption of innovative methods and technologies that increase the efficiency and quality of the entire translational research pipeline. Funding for this program is authorized under Sections 301 and 405 of the Public Health Service Act, as amended, and is governed by federal regulations including 42 CFR Part 52 and 2 CFR Part 200. The National Institutes of Health, within the Department of Health and Human Services, has issued this forecast to invite eligible organizations to submit applications. Proposals will undergo the NIH’s standard peer-review process, with funding awarded only to those deemed meritorious. The point of contact for inquiries is the Division of Clinical Innovation at NCATS, reachable via the provided email, and all applications must be submitted through the official grants portal listed in the posting.

Administration of Public Health Programs

POSTED

DEADLINE

The Next Generation of the Clinical and Translational Science Awards Program Trial Innovation NetworkThe Next Generation of the Clinical and Translational Science Awards Program Trial Innovation Network is a forecasted funding opportunity issued by the National Institutes of Health under the Department of Health and Human Services to accelerate the development and execution of multi-center clinical trials. The initiative aims to overcome systemic barriers in trial design and implementation by fostering innovation in areas such as safety monitoring, digital health technologies, genomic capacity, disease progression modeling, and leadership training. It seeks to establish a national platform for advancing the science of clinical research through scalable, efficient, and cost-effective solutions, positioning the network as both a practical engine for trial delivery and a laboratory for methodological discovery. Applications must be submitted by eligible organizations and will be evaluated through the NIH’s standard peer-review process, with funding decisions based on merit and potential impact. The opportunity is authorized under Sections 301 and 405 of the Public Health Service Act and governed by Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. While no specific set-aside or NAICS code has been designated, the announcement is open to all qualified applicants who meet the eligibility criteria outlined in the full notice. The forecast was posted on July 20, 2026, and point of contact for inquiries is the Division of Clinical Innovation at NCATS, reachable via tin@nih.gov. Further details and application guidance are available through the Grants.gov portal using the provided UI link, and submissions will follow the NIH’s standard review and selection protocols.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Limited Competition: Clinical and Translational Science Awards (CTSA) Program: Collaborative and Innovative Acceleration AwardThe Congressionally mandated Clinical and Translational Science Awards (CTSA) Program aims to accelerate the translation of scientific discoveries into practical treatments, diagnostics, and health interventions that enhance patient and public health by funding a national network of academic medical centers. This network provides essential infrastructure, expertise, training, and collaborative platforms needed to move research from the laboratory into clinical practice and community health settings. The current opportunity is a forecast for a limited competition soliciting applications for the Collaborative and Innovative Acceleration Award, designed to support the development and implementation of novel approaches, technologies, or models that amplify the impact of translational research and expedite the delivery of effective therapies to all populations. Funding is authorized under Sections 301 and 405 of the Public Health Service Act, and governed by Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. Eligible organizations may apply under this limited competition, and proposals will undergo standard National Institutes of Health peer review, with funding awarded only to meritorious applications. The announcement is issued by the National Institutes of Health, under the Department of Health and Human Services, with specific inquiries directed to the Division of Clinical Innovation at NCATS. The forecast was posted on July 20, 2026, and further details can be accessed through the official grants.gov listing, though no set-aside type, NAICS code, or specific place of performance is indicated.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

Elucidation and Validation of the role of Transporters in the Placenta, Lactating Mammary Gland, Developing Gut, and Blood Brain BarrierThe Eunice Kennedy Shriver National Institute of Child Health and Human Development is advancing its mission to improve maternal, fetal, and child health by launching a second phase of the Transporter Elucidation Network, focused on understanding how biological transporters and local metabolic processes regulate exposure to nutrients, medications, microbiome-derived compounds, and environmental chemicals across critical perinatal barriers. This initiative will develop comprehensive multi-barrier frameworks that connect the maternal gut, placenta, lactating mammary epithelium, infant gut, and infant blood-brain barrier, building on prior organ-specific research to create standardized models, resources, and prototype multi-compartment systems that reflect the dynamic interplay of transporters, their polarity, kinetics, and biotransformation capacities during pregnancy, lactation, and infant development. The goal is to deepen mechanistic insights into how these systems influence nutrient delivery, drug distribution, and neurodevelopmental outcomes in early life. This phase will establish community-wide resources to support integrated studies of perinatal exposure, risk assessment, and targeted interventions across linked maternal-fetal-infant systems, while strengthening collaboration among researchers and accelerating the sharing of tools and data. Emphasis is placed on human-based and developmentally relevant models to ensure biological accuracy and translational impact. The effort also aims to cultivate a next-generation workforce skilled in transporter science, fostering innovation in pediatric pharmacology and neonatal health. Authorized under 42 U.S.C. § 241, the initiative is being led by the Obstetric and Pediatric Pharmacology and Therapeutics Branch of NICHD, with inquiries directed to their designated point of contact, and the opportunity was publicly forecasted on July 16, 2026.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)The program aims to foster collaborative translational research between NIH intramural scientists and external extramural investigators to accelerate the translation of basic biological discoveries into clinical applications that improve health. It supports high-quality science with the potential to advance understanding of significant disease processes or lead to new diagnostics, therapeutics, or prevention strategies aligned with the priorities of participating NIH Institutes and Centers. The initiative specifically encourages partnerships that leverage the unique resources and expertise available within the NIH intramural research program, enabling extramural researchers to conduct clinical research in collaboration with NIH scientists. This effort is designed to strengthen translational science by bridging the gap between laboratory-based research and clinical implementation through integrated, multidisciplinary teams. The funding opportunity, titled Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional), is posted by the National Institutes of Health under the Department of Health and Human Services and is forecasted for release on July 16, 2026. It is open to both intramural and extramural investigators and allows for clinical trials as optional components. The primary point of contact for inquiries is the U01 Program team, reachable via email at nihirppartnerships@mail.nih.gov or by phone at 301-496-4121. Additional details and application information can be accessed through the Grants.gov portal at the provided link. The program does not specify a set-aside type, NAICS code, or physical office location, reflecting its national scope and administrative structure under NIH's broader research framework.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Limited Competition: NIMHD Initiative for Improving American Indian and Alaska Native Cancer Outcomes (U19 - Clinical Trial Optional)This opportunity, issued by the National Institutes of Health under the Department of Health and Human Services, is a forecast for a limited competition aimed at advancing research to reduce cancer incidence and mortality among American Indians and Alaska Natives, especially those in rural areas. The initiative, titled Limited Competition: NIMHD Initiative for Improving American Indian and Alaska Native Cancer Outcomes (U19 - Clinical Trial Optional), seeks to support projects focused on prevention, diagnosis, and treatment of cancer with the goal of generating practical, culturally relevant outcomes that directly benefit AI/AN communities and their families. Applications must come from eligible organizations, and proposals will undergo standard NIH peer review, with only meritorious submissions considered for funding. The opportunity is open to clinical trials but does not require them. Interested parties should note that the posting date is July 16, 2026, and inquiries can be directed to the NIMHD DCHPS Scientific Team at nimhddchpsscientificteam@mail.nih.gov.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)The National Cancer Institute is soliciting R33 grant applications to support the advanced development and rigorous validation of emerging technologies aimed at advancing cancer research and clinical care. This opportunity is intended for projects that have already addressed major feasibility barriers, as demonstrated by strong preliminary data, but require further refinement, optimization, and technical validation to achieve broad adoption within the scientific community. The focus is on technologies with new or substantially improved capabilities for measuring, analyzing, modeling, or interrogating cancer-related biological systems, including advanced molecular and cellular platforms, multi-omic and spatial profiling methods, next-generation imaging and sensing tools, immuno-engineering approaches, and innovations in biospecimen handling and quality assessment. Proposals must center on cancer-specific applications, and applications that merely apply established technologies to novel biological questions without technological innovation are not eligible. This funding opportunity is part of the NCI’s Innovative Molecular Analysis Technologies Program and explicitly prohibits clinical trials. The goal is to accelerate progress in areas such as cancer biology, early detection, diagnosis, treatment, control, and epidemiology by enabling technologies that offer transformative potential for the research community. Projects must demonstrate clear potential for widespread utility in cancer research while maintaining a tight focus on technical advancement rather than application-specific hypotheses. All applications must be submitted through the designated grants portal, and inquiries should be directed to the IMAT Program Contact provided. The opportunity was posted in July 2026 and is open to applicants seeking to bridge the gap between initial innovation and scalable adoption in cancer science.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE